Ruffer LLP Imv Inc. Transaction History

Ruffer LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$1.07 - $1.5 $403,647 - $565,861	-377,241 Reduced 7.86%	4,419,545 $6.28 Million
Q4 2021 Feb 04, 2022	SELL	$1.22 - $1.78 $886,467 - $1.29 Million	-726,613 Reduced 13.16%	4,796,786 $5.85 Million
Q3 2021 Nov 10, 2021	SELL	$1.35 - $2.16 $2.42 Million - $3.87 Million	-1,789,743 Reduced 24.47%	5,523,399 $9.26 Million
Q2 2021 Aug 06, 2021	SELL	$2.12 - $3.24 $297,344 - $454,432	-140,257 Reduced 1.88%	7,313,142 $15.8 Million
Q3 2020 Nov 12, 2020	BUY	$2.87 - $5.95 $1.87 Million - $3.88 Million	652,174 Added 9.59%	7,453,399 $33.4 Million
Q1 2019 May 10, 2019	BUY	$3.6 - $5.84 $2.35 Million - $3.81 Million	652,000 Added 10.6%	6,801,225 $27.3 Million
Q4 2018 Feb 07, 2019	BUY	$4.93 - $6.34 $30.3 Million - $39 Million	6,149,225 New	6,149,225 $31.3 Million

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Ruffer LLP, based on Form 13F filings with the SEC.

Stay updated on Ruffer LLP with notifications on news.